Navigation Links
Asymmetrex Partners in Manufacturing USA Institute
Date:1/23/2020

Asymmetrex LLC is part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is the 12th Manufacturing USA Institute. ARMI brings together a consortium of over 100 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs.

Approximately $80 million from the federal government will be combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities. As part of continuing efforts to help revitalize American manufacturing and incentivize companies to invest in new technology development in the United States, ARMI will lead the Advanced Tissue Biofabrication (ATB) Manufacturing USA Institute on behalf of the Department of Defense.

Under the umbrella of Manufacturing USA, a public-private network that invests in the development of world-leading manufacturing technologies, ARMI will work to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue Biofabrication technology to better position the US relative to global competition. ARMI will also focus on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing for critical Department of Defense and civilian needs.

“We need to develop 21st century tools for engineered tissue manufacturing that will allow these innovations to be widely available – similar to how a 15th century tool (the printing press) allowed knowledge to spread widely during the Renaissance,” said inventor Dean Kamen, ARMI’s chairman.

ARMI’s efforts are supported by forty-seven industrial partners, twenty-six academic and academically affiliated partners, and fourteen government and nonprofit partners. The ARMI partnership continues to grow.

About Asymmetrex
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations. For more information, please visit http://www.asymmetrex.com.

About ARMI
The Advanced Regenerative Manufacturing Institute (ARMI), headquartered in Manchester, NH, is the 12th Manufacturing USA Institute. It brings together a consortium of over 150 partners from across industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. ARMI will work to organize the current fragmented domestic capabilities in tissue Biofabrication technology to better position the U.S. relative to global competition. For more information on ARMI, please visit http://www.ARMIUSA.org.

Read the full story at https://www.prweb.com/releases/asymmetrex_partners_in_manufacturing_usa_institute/prweb16850755.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments
2. Asymmetrex Approved to Conduct an ASTM Interlaboratory Evaluation of Its AlphaSTEM Test™ Technology as a Standard for Counting Therapeutic Adult Tissue Stem Cells
3. Asymmetrex Presents Proposal for ASTM Interlaboratory Evaluation of AlphaSTEM Test™ Technology Towards Establishing A Standard for Counting Therapeutic Stem Cells
4. Asymmetrex Publishes Chapter Explaining the Critical Need for Stem Cell Dosing for Success in Stem Cell Medicine
5. Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About CRISPR-Cas9 Gene-Editing Therapies
6. Asymmetrex Proposes “Stemgene Therapy” to Emphasize the Importance of Tissue Stem Cells for Successful Gene Therapy
7. R3 Stem Cell Now Offering Complimentary Overnight Biologic Shipping for Practice Network Partners
8. Marque D. Todd, MS, DVM, DABT, Joins NDA Partners as Regulatory Toxicology Expert
9. Senior Regulatory Affairs and Program Management Executive, Robert Peterson, RAC, Joins NDA Partners
10. Former Vice President and Global Head of Quantitative Clinical Pharmacology at AstraZeneca Joins NDA Partners
11. Deep Science Ventures partners with Cancer Research UK, The World’s Largest Independent Funder of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... ... 2020 , ... Catalent, a global leader in clinical supply ... facility in Minakuchi, located in the Shiga prefecture of Japan. , Operating in ... new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving both ...
(Date:6/23/2020)... , ... June 23, 2020 ... ... of gene-to-protein and monoclonal antibody development services, today announced that the company ... and services to the pharmaceutical, diagnostics, and research industries. The decision to ...
(Date:6/19/2020)... ... June 16, 2020 , ... The director of stem cell biotechnology company ... cell medicine and pharmaceutical industries have easier access to stem cell counting, they will ... of this year, Independence Day weekend in the U.S., Asymmetrex is offering free tissue ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... The ... centers in 16 countries, has reached its 20th anniversary of worldwide use. Introduced ... use at top universities including University of Pennsylvania, University of Michigan, University of ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial ... early detection and prevention of high-burden diseases, and Centric Consulting, a business and ... organizations to utilize existing data in order to identify and prioritize patients for ...
(Date:7/10/2020)... , ... July 09, 2020 , ... ... cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as ... oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... launch of a new clinical diagnostics immuno-oncology service, TissueInsight . TissueInsight ... , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists ...
Breaking Biology Technology: